HALON-hysterectomy by transabdominal laparoscopy or natural orifice transluminal endoscopic surgery: a randomised controlled trial (study protocol)

Jan Baekelandt, Peter A. De Mulder, Ilse Le Roy, Chantal Mathieu, Annouschka Laenen, Paul Enzlin, Steven Weyers, Ben Mol, Jan Ja Bosteels

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

INTRODUCTION: Natural orifice transluminal endoscopic surgery (NOTES) uses natural body orifices to access the cavities of the human body to perform surgery. NOTES limits the magnitude of surgical trauma and has the potential to reduce postoperative pain. This is the first randomised study in women bound to undergo hysterectomy for benign gynaecological disease comparing NOTES with classical laparoscopy.

METHODS AND ANALYSIS: All women aged 18-70 years, regardless of parity, consulting at our practice with an indication for hysterectomy due to benign gynaecological disease will be eligible. After stratification according to uterine size on clinical examination, participants will be randomised to be treated by laparoscopy or by transvaginal NOTES. Participants will be evaluated on day 0, days 1-7 and at 3 and 6 months. The following data will be collected: the proportion of women successfully treated by removing the uterus by the intended approach as randomised; the proportion of women admitted to the inpatient hospital; postoperative pain scores measured twice daily by the women from day 1 to 7; the total amount of analgesics used from day 1 to 7; readmission during the first 6 weeks; presence and intensity of dyspareunia and sexual well-being at baseline, 3 and 6 months (Short Sexual Functioning Scale (SSFS) scale); duration of surgery; postoperative infection or other surgical complications; direct and indirect costs incurred up to 6 weeks following surgery. The primary outcome will be the proportion of women successfully treated by the intended technique; all other outcomes are secondary.

ETHICS AND DISSEMINATION: The study was approved on 1 December 2015 by the Ethics Committee of the Imelda Hospital, Bonheiden, Belgium. The first patient was randomised on 17 December 2015. The last participant randomised should be treated before 30 November 2017. The results will be presented in peer-reviewed journals and at scientific meetings within 4 years after starting recruitment.

TRIAL REGISTRATION NUMBER: NCT02631837; Pre-results.

LanguageEnglish
Pagese011546
JournalBMJ open
Volume6
Issue number8
DOIs
Publication statusPublished - 12 Aug 2016

Keywords

  • Hysterectomy
  • NOTES

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Baekelandt, Jan ; De Mulder, Peter A. ; Le Roy, Ilse ; Mathieu, Chantal ; Laenen, Annouschka ; Enzlin, Paul ; Weyers, Steven ; Mol, Ben ; Bosteels, Jan Ja. / HALON-hysterectomy by transabdominal laparoscopy or natural orifice transluminal endoscopic surgery : a randomised controlled trial (study protocol). In: BMJ open. 2016 ; Vol. 6, No. 8. pp. e011546.
@article{27792bad62674c8790a192d31b58459c,
title = "HALON-hysterectomy by transabdominal laparoscopy or natural orifice transluminal endoscopic surgery: a randomised controlled trial (study protocol)",
abstract = "INTRODUCTION: Natural orifice transluminal endoscopic surgery (NOTES) uses natural body orifices to access the cavities of the human body to perform surgery. NOTES limits the magnitude of surgical trauma and has the potential to reduce postoperative pain. This is the first randomised study in women bound to undergo hysterectomy for benign gynaecological disease comparing NOTES with classical laparoscopy.METHODS AND ANALYSIS: All women aged 18-70 years, regardless of parity, consulting at our practice with an indication for hysterectomy due to benign gynaecological disease will be eligible. After stratification according to uterine size on clinical examination, participants will be randomised to be treated by laparoscopy or by transvaginal NOTES. Participants will be evaluated on day 0, days 1-7 and at 3 and 6 months. The following data will be collected: the proportion of women successfully treated by removing the uterus by the intended approach as randomised; the proportion of women admitted to the inpatient hospital; postoperative pain scores measured twice daily by the women from day 1 to 7; the total amount of analgesics used from day 1 to 7; readmission during the first 6 weeks; presence and intensity of dyspareunia and sexual well-being at baseline, 3 and 6 months (Short Sexual Functioning Scale (SSFS) scale); duration of surgery; postoperative infection or other surgical complications; direct and indirect costs incurred up to 6 weeks following surgery. The primary outcome will be the proportion of women successfully treated by the intended technique; all other outcomes are secondary.ETHICS AND DISSEMINATION: The study was approved on 1 December 2015 by the Ethics Committee of the Imelda Hospital, Bonheiden, Belgium. The first patient was randomised on 17 December 2015. The last participant randomised should be treated before 30 November 2017. The results will be presented in peer-reviewed journals and at scientific meetings within 4 years after starting recruitment.TRIAL REGISTRATION NUMBER: NCT02631837; Pre-results.",
keywords = "Hysterectomy, NOTES",
author = "Jan Baekelandt and {De Mulder}, {Peter A.} and {Le Roy}, Ilse and Chantal Mathieu and Annouschka Laenen and Paul Enzlin and Steven Weyers and Ben Mol and Bosteels, {Jan Ja}",
year = "2016",
month = "8",
day = "12",
doi = "10.1136/bmjopen-2016-011546",
language = "English",
volume = "6",
pages = "e011546",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "8",

}

Baekelandt, J, De Mulder, PA, Le Roy, I, Mathieu, C, Laenen, A, Enzlin, P, Weyers, S, Mol, B & Bosteels, JJ 2016, 'HALON-hysterectomy by transabdominal laparoscopy or natural orifice transluminal endoscopic surgery: a randomised controlled trial (study protocol)', BMJ open, vol. 6, no. 8, pp. e011546. https://doi.org/10.1136/bmjopen-2016-011546

HALON-hysterectomy by transabdominal laparoscopy or natural orifice transluminal endoscopic surgery : a randomised controlled trial (study protocol). / Baekelandt, Jan; De Mulder, Peter A.; Le Roy, Ilse; Mathieu, Chantal; Laenen, Annouschka; Enzlin, Paul; Weyers, Steven; Mol, Ben; Bosteels, Jan Ja.

In: BMJ open, Vol. 6, No. 8, 12.08.2016, p. e011546.

Research output: Contribution to journalArticle

TY - JOUR

T1 - HALON-hysterectomy by transabdominal laparoscopy or natural orifice transluminal endoscopic surgery

T2 - BMJ Open

AU - Baekelandt, Jan

AU - De Mulder, Peter A.

AU - Le Roy, Ilse

AU - Mathieu, Chantal

AU - Laenen, Annouschka

AU - Enzlin, Paul

AU - Weyers, Steven

AU - Mol, Ben

AU - Bosteels, Jan Ja

PY - 2016/8/12

Y1 - 2016/8/12

N2 - INTRODUCTION: Natural orifice transluminal endoscopic surgery (NOTES) uses natural body orifices to access the cavities of the human body to perform surgery. NOTES limits the magnitude of surgical trauma and has the potential to reduce postoperative pain. This is the first randomised study in women bound to undergo hysterectomy for benign gynaecological disease comparing NOTES with classical laparoscopy.METHODS AND ANALYSIS: All women aged 18-70 years, regardless of parity, consulting at our practice with an indication for hysterectomy due to benign gynaecological disease will be eligible. After stratification according to uterine size on clinical examination, participants will be randomised to be treated by laparoscopy or by transvaginal NOTES. Participants will be evaluated on day 0, days 1-7 and at 3 and 6 months. The following data will be collected: the proportion of women successfully treated by removing the uterus by the intended approach as randomised; the proportion of women admitted to the inpatient hospital; postoperative pain scores measured twice daily by the women from day 1 to 7; the total amount of analgesics used from day 1 to 7; readmission during the first 6 weeks; presence and intensity of dyspareunia and sexual well-being at baseline, 3 and 6 months (Short Sexual Functioning Scale (SSFS) scale); duration of surgery; postoperative infection or other surgical complications; direct and indirect costs incurred up to 6 weeks following surgery. The primary outcome will be the proportion of women successfully treated by the intended technique; all other outcomes are secondary.ETHICS AND DISSEMINATION: The study was approved on 1 December 2015 by the Ethics Committee of the Imelda Hospital, Bonheiden, Belgium. The first patient was randomised on 17 December 2015. The last participant randomised should be treated before 30 November 2017. The results will be presented in peer-reviewed journals and at scientific meetings within 4 years after starting recruitment.TRIAL REGISTRATION NUMBER: NCT02631837; Pre-results.

AB - INTRODUCTION: Natural orifice transluminal endoscopic surgery (NOTES) uses natural body orifices to access the cavities of the human body to perform surgery. NOTES limits the magnitude of surgical trauma and has the potential to reduce postoperative pain. This is the first randomised study in women bound to undergo hysterectomy for benign gynaecological disease comparing NOTES with classical laparoscopy.METHODS AND ANALYSIS: All women aged 18-70 years, regardless of parity, consulting at our practice with an indication for hysterectomy due to benign gynaecological disease will be eligible. After stratification according to uterine size on clinical examination, participants will be randomised to be treated by laparoscopy or by transvaginal NOTES. Participants will be evaluated on day 0, days 1-7 and at 3 and 6 months. The following data will be collected: the proportion of women successfully treated by removing the uterus by the intended approach as randomised; the proportion of women admitted to the inpatient hospital; postoperative pain scores measured twice daily by the women from day 1 to 7; the total amount of analgesics used from day 1 to 7; readmission during the first 6 weeks; presence and intensity of dyspareunia and sexual well-being at baseline, 3 and 6 months (Short Sexual Functioning Scale (SSFS) scale); duration of surgery; postoperative infection or other surgical complications; direct and indirect costs incurred up to 6 weeks following surgery. The primary outcome will be the proportion of women successfully treated by the intended technique; all other outcomes are secondary.ETHICS AND DISSEMINATION: The study was approved on 1 December 2015 by the Ethics Committee of the Imelda Hospital, Bonheiden, Belgium. The first patient was randomised on 17 December 2015. The last participant randomised should be treated before 30 November 2017. The results will be presented in peer-reviewed journals and at scientific meetings within 4 years after starting recruitment.TRIAL REGISTRATION NUMBER: NCT02631837; Pre-results.

KW - Hysterectomy

KW - NOTES

UR - http://www.scopus.com/inward/record.url?scp=84995945475&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2016-011546

DO - 10.1136/bmjopen-2016-011546

M3 - Article

VL - 6

SP - e011546

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 8

ER -